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Abstract
Objective The coronary sinus Reducer is a recently intro-
duced device to treat patients with severe angina symptoms
refractory to optimal medical therapy and not amenable
for conventional revascularisation. We aimed to assess the
safety and efficacy of the Reducer in a real-world cohort of
patients with refractory angina.
Methods This is a single-centre retrospective registry. Pa-
tients with severe angina symptoms, objective evidence
of myocardial ischaemia using any adequate non-invasive
modality and without options for conventional revasculari-
sation were regarded eligible for Reducer implantation.
Results Twenty-three patients (74 % male, mean age 70±8
years, 91.3 % previous bypass surgery, 82.6 % previous per-
cutaneous intervention, 47.8 % previous myocardial infarc-
tion, 52.2 % diabetes mellitus) underwent Reducer implan-
tation. The safety endpoint (successful implantation of the
first device without device-related adverse events) was met
in all patients. After a median follow-up of 9 (8–14) months
the efficacy (any reduction in Canadian Cardiovascular So-
ciety (CCS) class and revascularisation-free survival) was
reached in 17 patients (74 %): 8 patients (34.8 %) improved
by 1 CCS class, 7 (30.4 %) by 2 CCS classes and 2 (8.7 %)
by 3 CCS classes. One patient died 4 months after implan-
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Conclusion In this single-centre real-world experience, Re-
ducer implantation was safe and demonstrated excellent
clinical efficacy in the treatment of refractory angina at
mid-term follow-up.
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Introduction
Despite the large armamentarium of anti-ischaemic medi-
cal therapies and revascularisation techniques, a consider-
able number of patients suffer from angina pectoris which
is refractory to medical treatment and related to coronary
artery disease (CAD) ineligible for conventional revascu-
larisation [1, 2]. In the light of the ageing population and
the increased life expectancy of CAD patients, the global
prevalence of refractory angina is expected to rise [2–4].
According to available data, refractory angina is diagnosed
in 5 to 15 % of coronary angiography candidates, which
implies approximately 30–50,000 new patients each year
in Europe [2], more than 500,000 in Canada and 1.8 mil-
lion in the United States [5], although robust epidemio-
logical data are lacking. Patients with refractory angina
are frequently hospitalised, use many anti-ischaemic drugs,
experience limited quality of life because of debilitating
symptoms, and are often strikingly young (with a mean age
65–70) [1, 6]. Therefore, treatments that relieve angina
symptoms and improve quality of life are urgently needed
for these no-option patients. A broad array of therapies
(e. g. novel medical treatment such as ivabradine and ra-
nolazine, internal mammary artery implants, extracorporeal
shockwave therapy, spinal cord stimulation, transmyocar-
dial laser revascularisation, gene therapy, cell therapy) have
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been investigated, none of which have become mainstream
[6–9].
Recently, the coronary sinus (CS) Reducer was intro-
duced into clinical practice as a new device-based treat-
ment for patients with refractory angina. This balloon-ex-
pandable stainless steel stent is designed to increase coro-
nary venous pressure by creating a focal stenosis in the
CS following its implantation. Coronary venous pressure
elevation alleviates angina by improving perfusion of the
ischaemic regions of the myocardium by increasing coro-
nary collateral blood flow [10, 11], redirecting flow to the
endocardium [11, 12], and possibly stimulating myocardial
neovascularisation [13]. The principle of enhancing my-
ocardial perfusion by elevating coronary venous pressure
was already described in 1936 by Gross and colleagues
[14] and was translated into clinical practice in 1954 by
Beck and Leighninger [15], who performed surgical partial
ligation of the CS in patients with angina pectoris (as part
of the Beck I operation).
Reducer implantation is the percutaneous equivalent of
surgical narrowing of the CS and shows promise as treat-
ment for refractory angina. Two small prospective registries
demonstrated a symptomatic improvement in the majority
(~85 %) of Reducer-treated patients, accompanied by a re-
duction in objective measures of myocardial ischaemia in
a subset of patients [13, 16]. Follow-up data indicated
durability of these results for up to 3 years [17]. The re-
cently published COronary SInus Reducer for treatment of
refractory Angina (COSIRA) trial firmly substantiated the
evidence base of CS narrowing by Reducer implantation as
treatment for refractory angina [18]. In this prospective,
multicentre, double-blind, sham-controlled trial the reduc-
tion of symptoms, in terms of the percentage of patients
whose Canadian Cardiovascular Society (CCS) functional
class improved as well as their quality of life, was sig-
nificantly larger in the treatment group compared with the
sham-controlled group after a 6-month follow-up period
[18].
Since 2014, Reducer implantations are performed in our
institution as part of clinical care. The aim of the present
study is to evaluate the safety and efficacy of CS Reducer
implantation in a real-world cohort of patients with refrac-
tory angina.
Methods
This is a single-centre, single-arm, retrospective study.
Patients were regarded as eligible for Reducer implanta-
tion when meeting the following criteria: 1) symptomatic
angina despite optimal pharmacological therapy; 2) ob-
jective evidence of inducible myocardial ischaemia, as
determined by bicycle stress electrocardiography, dobu-
tamine stress echocardiography, single-photon emission
computed tomography (SPECT), or stress magnetic reso-
nance imaging; and 3) proven CAD of the left coronary
artery not amenable for percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG), because
of unsuitable coronary anatomy, diffuse atherosclerosis,
or the absence of satisfactory landing zones for bypass
grafting, according to the decision of the local heart team.
When compared with the strict study enrolment criteria
of the COSIRA trial [18], no formal exclusion criteria were
considered for this real-world registry besides the presence
of ischaemia related exclusively to the right coronary artery
(also an exclusion criterion in COSIRA). As opposed to the
COSIRA trial, in which only patients with a positive dobu-
tamine stress echocardiography were included, any form of
proven ischaemia was accepted. Moreover, the presence
of pacemaker leads in the right heart was allowed. Only
patients with hardware already present in the CS (a left
ventricular pacemaker wire for cardiac resynchronisation
therapy (CRT)) were excluded. In our institution 4 patients
were included in the COSIRA trial: 2 in the treatment arm
and 2 in the sham arm. The 2 COSIRA participants from the
sham arm were included in the current registry as they un-
derwent Reducer implantation after the primary endpoint of
the COSIRA study was reached (6-month follow-up). The
2 COSIRA participants receiving the Reducer in the trial
were not included in the current registry.
Angina status was evaluated by an independent physi-
cian, who contacted all patients at follow-up by telephone.
Other relevant clinical endpoints, including death by any
cause, myocardial infarction and revascularisation, were
also recorded. The safety endpoint was defined as the suc-
cessful delivery of the first device in the proper location and
without any device-related adverse events. The efficacy
endpoint was defined as any reduction in CCS class and
revascularisation-free survival. All patients gave informed
consent for the procedure, and because of the retrospective
nature of the study, the requirement of approval from the
ethics committee was waived.
Device and implantation procedure
The Reducer is a percutaneous, endo-luminal, hourglass-
shaped, balloon-expandable stainless steel stent that is de-
signed for implantation in the CS to create a focal stenosis.
The device received CE approval for the treatment of re-
fractory angina in November 2011. It is available in one
single size that is suitable for a broad range of CS anatomies
(with a diameter between 9 and 13 mm).
All procedures were performed by one interventional
cardiologist (PA) with experience in Reducer implanta-
tion. The right jugular vein was punctured under local
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Fig. 1 Reducer implantation in patients with (A–C) and without presence of Dual-Chamber leads (D–F). Angiogram of the coronary sinus (A
and D), 9 French guiding catheter positioned deeply in the coronary sinus (B) implantation of the Reducer after retrieval of the 9 French guiding
catheter to the proximal part of the coronary sinus (C and E), angiographic control of the coronary sinus after Reducer implantation (F)
anaesthesia and 6 French multipurpose or Amplatz left
diagnostic catheter was introduced to selectively cannulate
and image the CS under fluoroscopic guidance. Once
the CS was deemed suitable for Reducer implantation,
a 9 French guiding catheter was advanced in the distal part
over a 0.035 inch guide wire with support of the diagnostic
catheter (mother-and-child technique). The Reducer, which
comes preloaded on the balloon, was then introduced over
the wire into the CS and positioned at the desired site. By
gentle retrieval of the guiding catheter, the Reducer was ex-
posed and implanted by inflating the delivery balloon. The
inflation pressure ranged between 2 and 6 atm according to
the diameter of the CS. An additional contrast injection via
the guiding catheter during inflation of the Reducer helped
to confirm slight oversizing as compared with the diameter
of the CS (Fig. 1).
The procedure was performed in a day-hospital setting.
Patients were discharged once proper closure of the access
site was confirmed. All patients continued their baseline
anti-anginal medication. Double antiplatelet therapy with
aspirin and clopidogrel was recommended for 1 month. In
case of oral anticoagulant therapy, additional clopidogrel
was mandated for 1 month.
Statistical analysis
Categorical variables are expressed as frequency and per-
centages. Continuous variables are expressed as mean and
standard deviation if normally distributed or as median (in-
terquartile range). Baseline and clinical follow-up data were
compared using the Wilcoxon signed-rank test. A two-
tailed probability value of < 0.05 was considered statisti-
cally significant. All statistical analyses were carried out
using the IBM Statistical Package for Social Science for
Windows, version 21.0 (IBM Corp., Armonk, NY, USA)
and GraphPad Prism, version 6.
Neth Heart J (2016) 24:544–551 547
Tab. 1 Baseline characteristics of patients receiving coronary sinus
Reducer
Overall (n = 23)
(n (%))
Age, years 70± 8
Gender, male 17 (74)
Body mass index, kg/m2 29± 4
Body surface area, m2 2.0± 0.2
Diabetes mellitus 12 (52.2)
Hypercholesterolaemia 13 (56.5)
Hypertension 14 (61.1)
Current or previous smoking 16 (69.5)
Familial coronary artery disease 20 (86.9)
Prior myocardial infarction 11 (47.8)
Prior percutaneous coronary intervention 19 (82.6)
Prior coronary artery bypass graft 21 (91.3)
Presence of pacemaker 4 (17.4)
Left ventricle ejection fraction, % 59± 9
Glomerular filtration rate, ml/min 68± 19





Long-acting nitrates 18 (78.2)
Calcium-channel antagonists 12 (52.2)
Beta-blockers 20 (86.9)
Results
In 2014, 23 consecutive patients (74 % male, mean age
70±8 years) with medically refractory angina without con-
ventional revascularisation options were electively treated
with the Reducer. One additional patient was refused fur-
ther screening for possible Reducer implantation because of
cardiac resynchronisation therapy hardware already present
in the CS. The majority of patients had a history of revascu-
larisation by means of PCI (82.6 %) and/or CABG (91.3 %).
The incidence of diabetes mellitus (52.2 %) and prior my-
ocardial infarction (47.8 %) was high. Despite being on
optimal anti-anginal treatment patients were severely symp-
tomatic, suffering from CCS class 3 to 4 symptoms, except
for one patient who had CCS 2 angina symptoms. Accord-
ing to nuclear imaging data (available for the majority of
the patients), the quantification of ischaemia was as fol-
lows: mean summed stress score of 11.94±7.18, summed
rest score of 6.69±7.54 and summed differential score of
6.41±4.61. The safety endpoint (successful delivery and
deployment at the planned implant site without any device-
related complications) was met in all patients. There were
no cases of device migration or cases of pericardial tampon-
ade. One patient suffered an access site haematoma, which
Tab. 2 Periprocedural outcomes
Overall (n = 23)
Preprocedural data
Coronary artery disease (untreated)
Diffuse microvascular problem 2 (8.6)
1-vessel disease 12 (52.2)
2-vessel disease 7 (30.4)
3-vessel disease 2 (8.6)








Procedural time, min 27± 4
Contrast volume, ml 52± 19
Radiation, mGy 480± 331
Fluoroscopy time, min 10 [8–17]
Access site complication, n (%) 1 (4.3)
Device embolisation, n (%) 0
Cardiac tamponade, n (%) 0
Intra-procedural death, n (%) 0
Safety endpointa, % 100
Post-procedural outcomes
Creatine kinase-MB, µg/l 3.8± 1.9
High sensitivity troponin, ng/l 298± 290
a successful placement of the device in the coronary sinus without any
periprocedural adverse events
was successfully treated in a conservative way. The patient
was hospitalised for observation for one night. Baseline
and procedural characteristics of the study population are
summarised in Tab. 1 and 2. Data for each individual case
are presented in Tab. 3.
After a median follow-up of 9 (8–14) months, the mean
CCS class was reduced from 3.4±0.6 at baseline to 2.1±1.0
at follow-up (p < 0.001). The efficacy (any reduction in
CCS class with revascularisation-free survival) was reached
in 17 patients (74 %): 8 patients (34.8 %) had improved by
1 CCS class, 7 (30.4 %) by 2 CCS classes and 2 (8.7 %) by
3 CCS classes. Failure to comply with the efficacy was due
to the absence of symptomatic improvement in 5 patients
(21.7 %) and repeat revascularisation in 1 patient (4.3 %)
(Fig. 2 and 3, Tab. 3). Of the 5 patients with no change in
CCS class, one underwent PCI of a saphenous vein graft
to the right coronary artery at the level of the anastomosis
with the right descending posterior artery 6 months after
Reducer implantation. This lesion was not visible on the
coronary angiogram performed 1 year before Reducer im-
plantation. One patient (with temporary improvement in
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Tab. 3 Individual patients characteristics
Patients characteristics at baseline Clinical outcomes
at follow-up







Location of ischaemia CCS Clinical events CCS
1a Female 68 – 71 Anteroseptal-apicalb 3 – 1
2 Female 69 – 63 Anterolateralb 4 – 3
3a Male 48 – 54 Inferolateralb 4 Repeat
revascularisation
2
4 Male 76 – 59 Inferolateralb 2 Repeat
revascularisation
2
5 Male 82 – 65 Inferior c 3 – 2
6 Male 65 – 62 Anterolateralb 3 – 1
7 Male 62 – Dual-Chamber 40 Anterolateralb 3 – 2
8 Male 66 Yes 59 Anteroapicalb 4 – 3
9 Female 76 – Dual-Chamber 67 Anteroseptal-apicalb 4 – 3
10 Male 75 – 64 Anteroseptal-apical-
inferiorb
3 – 1
11 Male 51 – 60 Anteroinferolateralb 4 – 1
12 Female 78 – 65 Anterolateralb 3 – 2
13 Female 62 Yes 65 Anteroseptal-lateralb 3 – 1
14 Male 73 – 50 Anterolateralb 3 Death 3
15 Male 75 – 46 Inferolateral-anteroseptalb 4 – 3
16 Male 72 – 51 Inferolateralb 3 – 1
17 Female 80 – 69 Lateralb 3 – 1
18 Male 80 – Dual-Chamber 52 Anterolateralb 4 – 4
19 Male 66 Yes 70 Anteroseptalb 3 – 1
20 Male 71 – 61 Anteroseptalb 3 – 3
21 Male 69 – 45 Septalb 4 – 1
22 Male 68 – Dual-Chamber 50 Inferolaterald 4 – 3
23 Male 73 – 60 Lateralb 4 – 4
a patients from current study who also participated in the control-arm of the COSIRA trial. Ischaemia detection method: b SPECT; c stress
echocardiography; d stress magnetic resonance. CCS Canadian Cardiovascular Society functional class
symptoms, but recurrence of angina) underwent revascu-
larisation of a recurrent in-stent chronic total occlusion of
an aberrant left main coronary artery 9 months after Re-
ducer implantation. This lesion was already known before
Reducer implantation, but was deemed extremely complex
to treat. Left main PCI was uneventful and the patient im-
proved by 2 CCS classes. Another patient whose symptoms
did not improve after Reducer implantation died due to pro-
gressive heart failure at 4-month follow-up. No autopsy was
performed.
Discussion
In the present study we evaluated the safety and efficacy
of Reducer implantation in a real-world cohort of patients
with angina symptoms refractory to optimal medical ther-
apy in the presence of CAD not amenable for revasculari-
sation. All devices were implanted in the proper position
without any device-related adverse events. In particular,
no periprocedural complications occurred in patients with
pacemaker leads (n = 4). Efficacy was high as the majority
(74 %) of patients demonstrated symptomatic improvement
free from additional revascularisation at a median follow-
up of 9 months.
The efficacy observed in this real-world population is
in line with prior studies. Any improvement in CCS class
was observed in 74 % of patients, which is intermediate
of the ~85 % reported in previous non-randomised studies
[13, 16] and the 71 % in the treatment arm of the COSIRA
trial [18]. The magnitude of angina alleviation was also
fairly comparable. Symptom reduction of ≥ 2 CCS classes
occurred in 39 % and 35 % of patients in the present study
and COSIRA, respectively, but was slightly more frequent
in the previous non-randomised studies, as 53 % and 45 %
of patients improved ≥ 2 CCS classes [13, 16]. Similar ef-
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Fig. 2 Canadian Cardiovascular Society (CCS) class of individual pa-
tients at baseline and 9 months after Reducer implantation
Fig. 3 Canadian Cardiovascular Society (CCS) functional class
changes after Reducer implantation (positive numbers mean improve-
ment). According to this figure, 17 patients improved at least 1 CCS
class
fectiveness of the Reducer across the studies was reflected
in the mean CCS class at baseline and follow-up: 3.4±0.6
vs. 2.1±1.0 in this study, 3.2±0.4 vs. 2.1±1.0 in COSIRA,
and 3.1 vs. 1.6 and 3.3±0.6 vs. 2.0±1.0 in the aforemen-
tioned registries [13, 16].
The observed treatment effect of Reducer implantation
may be partially attributable to a placebo effect, especially
when considering the subjective nature of the efficacy end-
point. In double-blinded trials evaluating refractory angina
therapies, up to 41 % of patients receiving placebo have
been reported to improve ≥ 2 CCS classes [6]. In order
to reliably contrast Reducer therapy with the placebo effect
of a sham procedure, extensive precautions were taken in
the pivotal COSIRA trial to maintain double-blind condi-
tions [19]. Impressively, the COSIRA trial still succeeded
in showing a clear benefit of Reducer implantation over the
sham procedure. Significantly more patients in the Reducer
group had symptomatic improvement of ≥ 2 CCS classes
(35 % vs. 15 %, p = 0.02), as well as improvement of
≥ 1 CCS class (71 % vs. 42 %, p = 0.003) at 6 months.
Moreover, the gain in quality of life as evaluated by the
Seattle Angina Questionnaire was more pronounced (17.6
vs. 7.6 points, p = 0.03) [18]. The unequivocal results
of COSIRA strongly suggest effectiveness of Reducer im-
plantation, but confirmation in larger trials is required as
the sample size was relatively small (n = 104).
The mechanisms underlying the reduction of angina
symptoms after Reducer implantation are not fully un-
derstood. However, two potential anti-ischaemic effects
of elevation of CS pressure have been hypothesised, both
related to the increased back pressure in the venules and
capillaries caused by CS pressure elevation. Several studies
observed increased flow in pre-existing collaterals between
the non-ischaemic myocardium and ischaemic myocardium
after CS narrowing/occlusion [10, 11, 20]. Enhanced coro-
nary collateral flow may result from the back pressure
exerted resistance to coronary flow into the non-ischaemic
myocardium, leading to a shift of flow to the low pressure
surroundings of the ischaemic myocardium [18]. Other
studies also suggest that elevated back pressure promotes
blood flow to the ischaemia-prone endocardium [11, 12].
Endocardial blood flow is often diminished in the presence
of epicardial coronary stenosis because of decreased perfu-
sion pressure and dysfunctional physiological mechanisms
to preserve endocardial flow during exercise (i. e. the lack
of sympathetically mediated constriction of subepicardial
vessels) [21]. Increased back pressure lowers resistance
in the endocardial vascular bed by inducing dilatation of
subendocardial capillaries, which increases flow and re-
stores the endocardial-to-subepicardial flow ratio. Both
increased collateral flow and redistribution of flow to the
endocardial layers of the myocardium reduce ischaemia
and may be responsible for angina alleviation after Re-
ducer implantation. On the long run, neovascularisation
may also be involved in the anti-ischaemic effect of Re-
ducer therapy. This was suggested in a classic histological
study that reported an ‘unusual degree of vascularity’ in
ischaemic myocardium after the Beck II operation (arteri-
alisation of the CS followed by partial ligation) in a canine
coronary occlusion model [22].
The notion that alleviation of angina by Reducer implan-
tation involves a true reduction in myocardial ischaemia is
reinforced by the significant changes in objective measures
of ischaemia that have been observed [13, 16]. Albeit in
small numbers of patients, a significant decrease in ST-seg-
ment depression during exercise tests, wall motion abnor-
mality scores on stress echocardiography, and defect extent
scores on SPECT have been detected 6 months after the pro-
cedure [13, 16]. In COSIRA there was only a trend towards
improved ischaemic parameters in the treatment group, as
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the study was not powered to detect differences in this end-
point [18]. The anti-ischaemic potential of elevation of CS
pressure is also apparent in other CS interventions. Inter-
mittent CS occlusion has been shown to provide myocar-
dial salvage during coronary occlusion, reducing myocar-
dial ischaemia severity [20] and infarct size [23]. However,
the beneficial effects of intermittent CS occlusion involve
other mechanisms besides CS pressure elevation, includ-
ing reopening of the microvasculature, wash out of toxic
metabolites, and activation of regenerative processes [24].
The absence of symptomatic improvement, observed in
15 to 30 % of cases [13, 16, 18], may be explained by un-
favourable coronary venous anatomy. Ubiquitous presence
of Thebesian veins, draining directly into the ventricular
chambers, may prevent coronary venous pressure from ris-
ing despite adequate narrowing of the CS [25].
Narrowing of the CS by Reducer implantation seems
a safe procedure as no device-related adverse events were
documented in our study. The only non-device related
complication comprised a relatively harmless access-site
haematoma. No device displacements occurred during the
procedure. Although no imaging studies were performed to
confirm preserved device position and stent patency at fol-
low-up, late migration or occlusion seems unlikely [26], as
demonstrated before by serial computed tomography evalu-
ation [13]. The absence of safety issues specifically related
to Reducer therapy is in accordance with previous studies
[13, 16, 18].
Patients treated in the current study had an average left
ventricle fraction ejection of 59±9 % without patients with
ejection fraction < 35 %, thus CRT implantation is definitely
not indicated in any of them. If necessary, it is easy to
dilate the narrowed central segment of the stainless steel
Reducer device with a simple balloon-dilatation technique.
This approach may allow future passage of a CS lead for
CRT.
Limitations
This study has some important limitations. In the first place,
its retrospective single-centre design and small sample size.
Furthermore, the largely subjective nature of the efficacy
(involving change in CCS class) and the lack of ischaemia
detection at follow-up to support the symptomatic improve-
ment with reductions in objective measures of ischaemia.
Finally, we did not provide a standard medical treatment
control group.
Conclusion
In this single-centre real-world experience, Reducer im-
plantation was safe and efficacious, as the majority of
refractory angina patients demonstrated symptomatic im-
provement at mid-term follow-up. Larger trials are eagerly
awaited to further build the evidence base of Reducer
implantation for refractory angina.
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